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http://dx.doi.org/10.1016/j.ccell.2014.09.007SUMMARYIt is well understood that antigen-presenting cells (APCs) within tumors typically do not maintain cytotoxic
T cell (CTL) function, despite engaging them. Across multiple mouse tumor models and human tumor
biopsies, we have delineated the intratumoral dendritic cell (DC) populations as distinct from macrophage
populations. Within these, CD103+ DCs are extremely sparse and yet remarkably capable CTL stimulators.
These are uniquely dependent on IRF8, Zbtb46, and Batf3 transcription factors and are generated by
GM-CSF and FLT3L cytokines. Regressing tumors have higher proportions of these cells, T-cell-dependent
immune clearance relies on them, and abundance of their transcripts in human tumors correlates with clinical
outcome. This cell type presents opportunities for prognostic and therapeutic approaches across multiple
cancer types.INTRODUCTION
In immunoevasive tumors, a complex microenvironment de-
velops alongside the lesion, and despite the recruitment of
CD8 T cells, there is no effective control of the developing
mass. This microenvironment is prominently composed of the
mononuclear phagocytic lineage (MPS) in addition to tumor-
associated fibroblasts (TAFs) and a variety of additional immune
infiltrates, including neutrophils and tumor-specific T cells (Ha-
nahan and Weinberg, 2011; Kraman et al., 2010). A primary
conundrum at present is to understandwhy the latter cells, whichSignificance
Current cancer immunotherapies are based on enhancing the a
efficient CTL function requires frequent repriming and abund
margin, either fail to achieve this, and/or actively inhibit T cell
in tumors have a functional opposite, in the form of antigen-pr
tumor antigens and are differentially distributed within the tu
describe how intratumoral CD103+ DCs are uniquely targeta
mice, and how their transcript prevalence predicts outcome in
638 Cancer Cell 26, 638–652, November 10, 2014 ª2014 Elsevier Incinclude CD8+ T cells with the potential to kill the tumor, ultimately
fail to do so.
The MPS lineage typically should have the potential to present
antigens to T cells by virtue of their phagocytic capacity. In tu-
mors, the infiltrating MPS lineage has been described as
comprising tumor-associated macrophages (TAMs; see Lewis
and Pollard, 2006), tumor dendritic cells (DCs), as well as mono-
cytes. While monocytes do not clearly function as APCs, they
may act at minimum as precursors to TAMs and DCs in normal
and transformed tissues (Cheong et al., 2010; Cortez-Retamozo
et al., 2012; Geissmann et al., 2010). A number of studies havebility of host or introduced T cells to reject tumors. However,
ant tumor macrophages, which capture CTL at the tumor
responses. Here we show that the abundant macrophages
esenting CD103+ DCs. These cells efficiently cross-present
mor microenvironment compared with tolerizing APCs. We
ble, how their abundance is required for T cell therapy in
human cancers.
.
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CD103+ DCs Drive T-Cell-Mediated Tumor Rejectionimplicated specific MPS-lineage-derived cells, particularly
immature monocytes, in dampening the responsiveness of cyto-
toxic T cells (CTLs) in tumors (Kusmartsev et al., 2005). Through
intravital imaging, we and others have found that antigen-spe-
cific CD8+ T cells are initially captured in prolonged interactions
with myeloid cells, along the tumor border (Boissonnas et al.,
2013; Engelhardt et al., 2012). In those experiments, the myeloid
cells that phagocytosed tumor antigens and cross-presented
them, when purified in aggregate, failed to stimulate T cells
in vitro. Thus, by all criteria to date, the immune microenviron-
ment is a combination of poorly stimulatory and/or actively inhib-
itory APC partners for CTLs. While depletion of regulatory T cells
and checkpoint blockades are suggested to broadly license
tumor APCs (Curran et al., 2010), there has been no evidence
of strongly stimulatory APCs within the native tumor.
As immunotherapies targeting costimulatory blockade (Leach
et al., 1996) move to the forefront of cancer therapeutics, it
becomes increasingly important to understand the spatial and
temporal context of costimulation and antigen presentation.
Antigen presentation at the lymph node (LN) for priming of tu-
mor-reactive T cell expansion is clearly critical and as such has
been successfully targeted therapeutically usingGM-CSF (Dran-
off, 2002) to increase presentation in the LN. As such, much of
the focus has remained on the LN despite our clear understand-
ing that antigen presentation also occurs within the tumor itself
and likely influences the functions of tumor CTLs.
It was therefore our goal to dissect the distinct composition of
themyeloid tumor microenvironment across a broad range of tu-
mors, with the purpose of understanding the lineage relation-
ships among these populations and how each influenced tumor
T cell responses and outcome.
RESULTS
Surface Markers Delineate Rare Tumoral DC Subsets
from Abundant Macrophages
To dissect the tumor-infiltratingmyeloid populations, we devised
an 11-color flowcytometry panel and progressive gating strategy
using a spontaneous breast tumor model, PyMTChOVA
(Engelhardt et al., 2012), engineered along with the initiating
oncogene to independently coexpress fluorescent mCherry pro-
tein and ovalbumin. We profiled the tumoral CD45+ compart-
ment, many of which had phagocytosed tumor antigen and
thus exhibit mCherry fluorescence (Figure 1A). Subgating all he-
matopoietic cells by the myeloid-specific marker CD11b and the
monocyte marker Ly6C allowed removal of neutrophils and
monocytes (see Figure S1A available online). Within the MHCII+
cells, DCs were distinguished from macrophages based on
CD24hi and F4/80lo expression, neither of which alone is suffi-
cient to make this distinction. Subsequently, DCs were found
to parse into two populations based on differential expression
ofCD11b andCD103, as has been observed in healthy peripheral
tissues (Hashimoto et al., 2011). We found these populations in
two mouse models of melanoma (B78ChOVA, a variant of B16
expressing mCherry and OVA, Figure 1B, and BRAF V600E, Fig-
ure S1B), across mouse strains (e.g., FVB PyMT; Figure S1B),
and in ectopic tumors (Lewis Lung Carcinoma; Figure S1B). We
refer to these DC populations as ‘‘CD11b+ DC1’’ and ‘‘CD103+
DC2’’ henceforth for ease of discrimination and discussion.CanParsing of the F4/80hi CD24lo compartment also revealed two
types of macrophages, identified by differential expression of
CD11c and CD11b. CD11clo CD11bhi (heretofore ‘‘TAM1’’) and
CD11chi CD11blo cells (‘‘TAM2’’) appear to broadly correspond
to similarly delineated MHCIIhi and MHCIIlo populations (Mova-
hedi et al., 2010) (see Figure 5C). While CD11c, otherwise a ‘‘pro-
totypical’’ DC marker, was highest on DCs, it was highly
expressed in TAM2 and to a lesser extent in TAM1 (Figure S1C).
These populations existed across all models examined, although
the prevalence of each and their ability to be unambiguously
distinguished varied slightly (Figures 1A, 1B, and S1B). For the
rest of this report, we therefore applied our lineage and function
studies to one example of spontaneous (PyMTChOVA) and
ectopic tumor model (B78ChOVA), except where indicated.
mCherry loading and retention, derived from the tumor, were
assessed for each of these populations. This revealed that the
uptakehi cells, localized to the tumor margin in our previous
report and then identified only by CD11c (Engelhardt et al.,
2012), were best captured in the TAM1 and TAM2 gates (Figures
1C and S1D). Comparatively, CD11b+ DC1s and CD103+ DC2s
took up or retained less mCherry while some monocytes but
few neutrophils showed evidence of modest antigen loading.
CD11b+ andCD103+ DC subsets have been found inmany pe-
ripheral mouse tissues, and their counterparts have been identi-
fied in peripheral human tissues, defined by expression of
BDCA1 and BDCA3, respectively (Dzionek et al., 2000; Haniffa
et al., 2012). We found that an equivalent TAM/DC distinction
was also possible in humanmetastatic melanoma samples using
these markers (Figure 1D). CD16HLADR+ CD11c+CD14+ cells
representing all TAMs were distinct from CD16HLADR+
CD11c+CD14DCpopulations, whichwere in turn parsed by dif-
ferential expression of BDCA1 (‘‘DC1’’) and BDCA3 (‘‘DC2’’).
Common across mouse models (Figure 1E) and human mela-
noma biopsies (Figure 1F) are the presence and rarity of the
CD11b+/BDCA1 DC1 and CD103+/BDCA3 DC2 populations,
with DC2 being particularly sparse.
Protein and Transcriptional Delineation of Tumor DCs
and Macrophages
To validate our gating strategies, we applied panels of antibodies
defined by the ImmGen consortium (Gautier et al., 2012; Miller
et al., 2012). Consistent with our assignment of ‘‘DC,’’ CD103+
DC2 expressed CD135 FLT3 CD117 (cKit), and CD26, whereas
both TAM populations did not in the B78chOVA and
PyMTchOVA models (Figures 2A and S2A). Surprisingly,
CD11b+ DC1 did not express detectable levels of DC markers
and actually segregated more with TAM1 and TAM2 by virtue
of expression of several ‘‘macrophage’’ markers, including
CD206, CD64, and MerTK (Figures 2B and S2B). CD11b+ DC1,
however, slightly expressed CD301b and PDL2, both of which
have been used to define IRF4-dependent ‘‘DCTh2’’ populations
found in the skin (Figures 2C and S2C) (Gao et al., 2013; Kuma-
moto et al., 2013).
To further delineate these APCs, we analyzed the gene
expression profiles of sorted cells from B78chOVA tumors using
RNAseq. As shown in Figure 2D, blocks of genes clearly segre-
gate the four populations, with TAM1, TAM2, and CD11b+ DC1
being the most similar by PCA analysis (Figure 2E) and CD103+
DC2 the most distinct. Among the genes most differentiallycer Cell 26, 638–652, November 10, 2014 ª2014 Elsevier Inc. 639
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Figure 1. Rare DC and Abundant Macrophages in Mouse and Human Tumors
(A–C) Representative of greater than five independent experiments. (A) Flow cytometry and gating of tumor APC populations from digested and CD45-enriched
PyMTchOVA tumors. (B) Cytometry of tumor APC populations in ectopic B78ChOVA tumors. (C) Histogram of tumor-derived mCherry fluorescence by tumor-
infiltrating immune cells in B78chOVA.
(D) Representative cytometry of digested humanmelanomametastatic biopsy identifying corollary DC and TAMpopulations defined byCD45+ Lin (CD3e, CD56,
CD19) HLA-DR+ and split by CD14, BDCA1, and BDCA3. Double-negative cells likely reflect B cells escaping lineage gate, immature monocytes, or pDC.
(E) Relative proportions of tumor infiltrating myeloid cells as a percentage of total CD45+ cells for PyMTchOVA and B78chOVA models. Pooled data from in-
dividual tumors are presented as mean ± SEM (n = 5) from mice.
(F) Frequency of DC and TAM populations infiltrating human metastatic melanoma presented as a percentage of total CD45+ cells. Pooled data from multiple
patients are presented as mean ± SEM from (n = 4) biopsies.
See also Figure S1.
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CD103+ DCs Drive T-Cell-Mediated Tumor Rejectionexpressed, DC lineage-defining transcription factors Irf8 (Ta-
mura et al., 2005) and Zbtb46 (zDC) (Meredith et al., 2012)
were specific for CD103+ DC2 alone, or both DCs, respectively,
whereas Irf4 was modestly enriched in CD11b+ DC1 and all of
which were validated by quantitative RT-PCR (qRT-PCR)
(Figure 2F). This was also confirmed at the protein level by intra-640 Cancer Cell 26, 638–652, November 10, 2014 ª2014 Elsevier Inccellular flow cytometry for IRF4/8 (Figures 2G and S2D). All pop-
ulations expressed Myb, which indicates hematopoietic stem
cell origin as opposed to deriving from tissue precursors, seeded
from the yolk sac (Schulz et al., 2012).
As these intratumoral populations may derive through distinct
tumor-specific mechanisms and not rely on these transcription.
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Figure 2. Surface and Transcriptional
Profiling Highlights Distinct Lineages of
Tumor DCs and Macrophages
(A) Expression of a panel of DC specific markers
comparedwith respective isotype (gray shaded). A
black box outlines the CD103+ DC2 population.
(B) Differential expression of Macrophage specific
markers (colored) with corresponding isotypes
(gray shaded). A black box outlines the CD11b+
DC1, TAM1, and TAM2 populations.
(C) Specific expression of DC-Th2 makers
(colored) by CD11b+ DC1 populations compared
with respective isotype (gray shaded). A black box
outlines CD11b+ DC1.
(D) Global transcriptional profiles revealed by
RNAseq of FACS-purified populations from
biological triplicates. Data are displayed as a
heat map of log2-fold change relative to the
global average of the top 1,000 genes by
maximum variance between DC1, DC2, TAM1,
and TAM2.
(E) PCA of DC1, DC2, TAM1, and TAM2 pop-
ulations based on RNAseq global transcriptional
profiles.
(F) qRT-PCR analysis of expression of Irf4, Irf8,
Myb, and Zbtb46 (zDC) from sorted APC pop-
ulations. Data are presented as mean D Ct ± SEM
calculated from biological triplicates (n = 3) (N.D.,
not detected).
(G) Intracellular staining for IRF4 and IRF8 in tumor
APC populations as compared with the respective
isotype (gray).
All data are from the ectopic B78chOVA tumor
model. Cell lineages are defined as in Figure 1. See
also Figure S2.
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CD103+ DCs Drive T-Cell-Mediated Tumor Rejectionfactors as they do in some normal tissues, we investigated IRF8,
IRF4, Batf3, and zDC dependency using knockout or transcrip-
tion-factor-driven diphtheria toxin receptor (DTR) mice. We
took advantage of various ectopic tumors, due to the vagaries
and length of breeding these alleles to a spontaneous model.
Using an ectopic PyMT breast tumor model, we found that
loss of Irf8 specifically ablated the CD103+ DC2s but did not
affect TAM1 or TAM2 and mildly enriched the percentage of
CD11b+ DC1, perhaps as a result of compensation (Figure 3A).
Conversely, conditional deletion of Irf4, driven by CD11c-Cre
(Williams et al., 2013), resulted in the specific reduction in
CD11b+ DC1 with little change in the others in the B78chOVA
model (Figure 3B). In agreement with RNAseq data, Batf3-defi-
cient animals also lacked tumoral CD103+ DC2 populations in
a B78chOVA model, without effect on CD11b+ DC1, TAM1, or
TAM2 proportions (Figure 3C). Finally, when a zDC-driven DTR
allele was used, we somewhat unexpectedly found a specific
and significant reduction in CD103+ DC2with little or no changes
in the CD11b+ DC1 or TAM1/TAM2 populations in B78chOVA
tumors (Figure 3D). This may represent vagaries of the DTR allele
or subtle but significant variations in zDC expression. Taken
together, we conclude that CD103+ DC2 represents a distinct
lineage of APC as compared with CD11b+ DC1 and the highly
abundant TAM1/TAM2 in the tumor.CanCD103+ DC2 Are Programmed by Distinct Cytokines
APCs derive from bonemarrow (BM) precursors, and their differ-
entiation into DC/macrophage subsets depends on specific
cytokines. To determine the cytokines driving differentiation
into these populations, we queried colony-stimulating factor
(CSF) receptor expression across models by qPCR. Whereas
Csf1r (M-CSFR) was found exclusively in TAM1, TAM2, and
CD11b+ DC1, Csf2rb (GM-CSFR) was uniquely expressed in
the DC1 and DC2 subsets, and Csf3r (G-CSFR) was absent in
all (Figure 4A). Using either neutralizing antibody treatment or
cytokine-receptor-deficient mice with ectopic tumors, we func-
tionally tested CSF cytokine reliance of the APCs at the tumor.
While TAM1 and TAM2 cells critically relied on CSF1 for their
maintenance, as has been shown previously (Wyckoff et al.,
2004), CD11b+ DC1 and CD103+ DC2 populations were uniquely
independent of CSF1 (Figure 4B). For use of cytokine receptor-
deficient mice, we developed a congenic adoptive transfer
model, whereby granulocyte macrophage progenitors (GMPs)
were transferred into ectopic tumor-bearing hosts and repopula-
tion was tracked in the BM, spleen, and tumor (Figure 4C). At the
tumor GMP-derived cells populated all myeloid compartments,
confirming GMP origin of CD11b+ DC1, CD103+ DC2, TAM1,
and TAM2 (Figure 4D). By use of the GMP adoptive system
with a competitive transfer, we found a selective inability ofcer Cell 26, 638–652, November 10, 2014 ª2014 Elsevier Inc. 641
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Figure 3. Differential IRF4, IRF8, and Batf3 Requirements for Tumor-Infiltrating APC Populations
(A) Ectopic PyMT-VO tumors from an Irf8/ (KO) compared with control (wild-type [WT]). Relative cell proportions are shown as a percentage of total MHCII+
cells. Data are pooled from individual mice (n = 6) from two independent experiments.
(B) Ectopic B78chOVA tumors in Irf4f/f x Cd11c-Cre+ host compared with Cre-negative littermates. Relative cell proportions are shown as a percentage of total
MHCII+ cells. Data are pooled from individual mice (n = 7) from two independent experiments.
(legend continued on next page)
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CD103+ DCs Drive T-Cell-Mediated Tumor RejectionCsf2rb/ cells to reconstitute DCs at the tumor, here defined as
the sum of DC1/DC2 using CD24+ CD11c+ gating. We found no
effect on TAM1 and TAM2 repopulation, suggesting a unique
requirement of CSF2 (GM-CSF) for tumoral DC development
(Figure 4E) while no requirement for CSF-3 was found for any
of the four APCs (Figure S3).
As DCs are prototypically driven by GM-CSF or FLT3-ligand
(FLT3L), we assessed cytokine sufficiency to drive DC popula-
tions at the tumor using B16 melanoma tumor models engi-
neered to express GMCSF or FLT3L. While GMCSF expression
by the tumor drastically skewed the proportion of CD11b+
DC1, FLT3L expressing tumors drove unique expansion of the
rare CD103+ DC2 at the tumor (Figure 4F).
Unique Antigen Processing and Presentation
Capabilities of CD103+ DC2
Having established the lineage requirements of the different
APCs, we then assessed their ability to initiate, engage, and sus-
tain T cell responses. Toparse the cellswith regard toantigenpro-
cessing, presentation, and costimulation, we analyzed transcript
andprotein levelsof genes involved in thesepathwaysusingRNA-
Seq data from Figure 2. Differences were considerable, across
broadswaths of potential APC function (Figure 5A).Notably,while
surface levelsofmolecules involved in regulatingTcell responses,
includingCD80, CD86, and 2B4, were comparable between pop-
ulations,CD103+DC2sshoweddistinct transcriptional signatures
consistent with heightened cross-presentation, enhanced costi-
mulation, and increased expression of chemokines that would
be expected to enhance T cell interactions (Figures 5A, 5B, and
S4A). There were no major differences in MHCI and MHCII
expression between the APCs with the exception of slightly
reduced MHCI on CD103+ DC2 (Figure 5C). However, significant
differences in phagocytic capacity were observed in CD103+
DC2s compared with TAM1/TAM2, measured exogenously by
ex vivo dextran uptake from ectopic tumors (Figure 5D).
As DC maturation and phagocytic capacity are often inversely
correlated, we hypothesized that the decreased phagocytic
capacity of CD103+ DC2 might correspond to a more mature
DC with increased cross-presentation of antigen (Guermonprez
et al., 2002). Efficient cross-presentation of antigen in DCs relies
on NOX2 to regulate phagasomal pH, thereby preventing
destruction of T cell peptides, which can be determined using
a ratiometric assay comparing intracellular fluorescence inten-
sity of a pH-sensitive and pH-insensitive fluorophore following
phagocytosis (Savina et al., 2006). We therefore generated a
B78 tumor line expressing a fusion of a pH-sensitive GFP
(pHluorin, quenched below pH 6.5) and a pH-insensitive fluoro-
phore (mCherry). By analyzing pHluorin intensity alone within
the mCherry+ compartment of each population, we found that
only the ‘‘DC’’ populations maintained pHluorin in an alkaline
(fluorescent) environment; comparing the ratio of pHluorin and
mCherry signals showed that CD103+ DC2 maintained the(C) Ectopic B78chOVA tumors in Batf3 KO compared with WT. Relative cell pro
individual mice (n = 6).
(D) Ectopic B78chOVA tumors in Zbtb46-DTRmice receiving acute 24 hr depletio
MHCII+ cells. Data are pooled from individual mice (n = 6) from two independent
All data are representative flow cytometric analysis of CD11b+DC1 and CD103+D
as mean ± SEM. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p
Canmost basic endocytic compartment, while TAM1 and TAM2 pop-
ulations displayed highly acidic and therefore degradative
phagocytic pathways (Figure 5E). In addition to the increased
alkaline phagosomal lumen of CD103+ DC2, these cells demon-
strated differential expression of the proinflammatory cytokine
interleukin-12 (IL-12) and absence of anti-inflammatory IL-10
(Figures 5F, 5G, and S4B). Together, all of these features suggest
CD103+ DC2s are highly poised for efficient antigen cross-pre-
sentation to CD8+ T cells.
CD103+ DC2s Are Superior Stimulators of Naive and
Activated CD8+ T cells
Previously, we found that the aggregate antigen-ingesting
myeloid compartment could stimulate naive but not previously
activated CD8+ T cells when taken directly from tumors (Engel-
hardt et al., 2012). However, based on the unique cross-presen-
tation phenotype of CD103+ DC2, we sought to test the T cell
stimulatory capacity of each population, freshly isolated from tu-
mors. After 12 hr of coculture with ovalbumin-specific OT-I CD8+
T cells, the CD103+ DC2 population was the only population
capable of robustly inducing TCR signaling, measured by GFP
expression driven by a Nur77 reporter (Nur77GFP) and CD69
levels in both naive and previously activated OT-I CD8+ T cells.
Importantly, this was consistent in both ectopic and sponta-
neous mouse models (Figures 6A and S5A). Extended coculture
of dye-labeled OT-I CD8+ T cells revealed that CD11b+ DC1 and
CD103+ DC2 populations were the most robust stimulators of
naive CD8+ T cell proliferation and demonstrated that nearly
the entire stimulatory capacity previously identified in phagocy-
tosing tumor myeloid cells lies within these DC (Figures 6B,
6C, S5B, and S5C). Interestingly, CD103+ DC2 were uniquely
capable of inducing strong proliferation of established CTLs,
which were not stimulated by the other populations, indicating
that CD103+ DC2 were superior cross-presenting stimulators
of CTLs in the tumor (Figures 6D, 6E, and S5D, respectively).
Ultimately, at their normally low frequencies in total tumor
isolate, CD103+ DC2s remain unable to drive proliferation of
CTLs (Figure S5E; Engelhardt et al., 2012). Additionally, none
of the APC subsets induced CD4+ T cell proliferation directly
from the tumor (Figures 6F, 6G, and S5F). However exogenous
peptide did restore DC1 and DC2 capacity to stimulate prolifer-
ation, suggesting these DCs may not be inherently incapable of
CD4 T cell stimulation (Figure S5G). Critically, this identifies the
unique capacity of CD103+ DC2 within the tumor to uptake, pro-
cess, and cross-present tumor antigen to robustly stimulate
CTLs. This challenges the simple concept that tumors contain
only weak or suppressive myeloid populations.
CD103+ DC2 Localization and T Cell Interactions
Revealed by Intravital Imaging
Given the unique ability of the rare CD103+ DC2s to stimulate
T cells, we sought to understand the spatial organization of theseportions are graphed as a percentage of total MHCII+. Data are pooled from
n with DT or PBS. Relative cell proportions are graphed as a percentage of total
experiments.
C2 populations (gated on CD45+, Ly6C, MHCII+, and CD24+). Data are shown
< 0.001; ns, not statistically significant.
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Figure 4. Differential Reliance on M-CSF and GM-CSF Cytokines by Tumor-Infiltrating APC Populations
(A) qPCR of Csf1r, Csf2rb, and Csf3r expression from sorted APCs. Data are presented as mean D Ct ± SEM calculated from biological triplicates (n = 3) of
individual B78chOVA tumors (N.D., not detected).
(B) Cytometry of tumor APCs after 3 days of aCSF1 (aCSF1, dotted) compared with isotype (filled)-treated tumor animals. Quantified as a percentage of total
tumor CD45+ cells, pooled from individual mice (n = 6) from two independent experiments shown asmean ± SEM. Statistical significance is indicated by *p < 0.05,
**p < 0.01, ***p < 0.001 (ns, not statistically significant).
(C) Schematic of BM progenitor adoptive transfer and contributions to BM, spleen, and tumor.
(D) Representative cytometry of tumor-arriving congenic cells; gated on CD45.2 and following the gating strategy of Figure 1A.
(E) Competitive BM adoptive transfer of WT versus Csf2rb KO GMP progenitors into B78chOVA tumor recipients. Repopulation efficiency is plotted as the
percentage of total transferred cells. This is representative gating of tumor arriving GMP cells, WT (gray), KO (purple). Quantification of tumor-arriving DCs is
defined by CD24+ CD11c+. Data are pooled from two independent experiments and plotted as mean ± SEM from individual tumors (n = 6).
(legend continued on next page)
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CD103+ DCs Drive T-Cell-Mediated Tumor Rejectioncells within tumors and their interaction dynamics with T cells
both in vivo and in vitro. To differentiate these populations in
living spontaneous tumors in vivo, the PyMTchOVA allele was
crossed on to Cx3cr1-eGFP and Cd11c-mCherry alleles, gener-
ating three uniquely fluorescent populations in the myeloid
compartment (Figure 7A). Both DC1 and DC2 subsets were
marked red (mCherry only), while TAM1 and TAM2 populations
were green (eGFP only) and yellow (mCherry and eGFP), respec-
tively. Using this model, with two-photon intravital imaging, we
observed that TAM1 and TAM2 populations are preferentially
marginating tightly on tumoral lesions. This zone is one where
we had previously found T cells to be preferentially captured (En-
gelhardt et al., 2012). In contrast, DC subsets typically were
found in separate collagen-rich zones distal to the tumor lesions,
making up nearly 70% of all distally localized APC (Figure 7B).
Since this approach did not fully differentiate between CD11b+
DC1 and CD103+ DC2 cells among those on the margins of tu-
mor foci, we sought to determine whether the few red DCsmight
preferentially represent exclusively one or the other subset. To
delineate the subsets in situ, we utilized live tumor slice imaging,
with anti-CD11b antibody staining. Using this, we could distin-
guish CD11b+ DC1 from CD103+ DC2 subsets in situ in the pres-
ence of the red/green fluorescent reporters and found that both
CD11b+ and CD11b DCs were present at these locations
(Figure 7C; Movie S1). We conclude that while TAMs generally
represent the dominant cell type at the tumor margin pro-CTL
stimulatory APCs nevertheless can be found there, albeit in
very low numbers.
Our previous data demonstrated that incoming CTLs engaged
in arrest behavior at the tumor margin, and we sought to deter-
mine whether these might be taking place with DCs or TAMs
or both. In vivo T cell dynamics were analyzed in the red/green
reporter system by adoptive transfer of CFP expressing OT-I
CD8+ T cells into spontaneous breast tumor-bearing mice, for
either intravital or live slice imaging. We observed stable T cell in-
teractions largely confined to the tumor margins, as previously
described (Boissonnas et al., 2013; Engelhardt et al., 2012) (Fig-
ures 7D and 7E; Movie S2). Although TAM1 interactions domi-
nated all interactions scored, DCs and TAM2s were also well
represented in T cell arrests. This demonstrates that DC1/DC2
in the tumor-proximal regions are not incapable nor physically
excluded from engaging T cells within tumors but did raise a
fundamental question of whether either is intrinsically more
capable of engaging T cells.
To answer this, we divorced APC selection from the physical
constraints of the tissue and digested tumor to make single-cell
suspension and introduced in vitro activated OT-I CTLs and al-
lowed them to form antigen-specific couples. We then quantified
the percentage of each APC population that was occupied with a
T cell by flow cytometry. This revealed that OT-I T cells couple
preferentially with CD103+ DC2 and TAM1/TAM2 subsets (Fig-
ure 7F, left panel). However, due to the high frequency of
TAM1/TAM2, most T cell-APC couples are formed with TAM1/
TAM2 cells (Figure 7F, right panel). We conclude that DC2s(F) Cytometry of CD11b+ DC1 and CD103+ DC2 populations (gated on CD45+, Ly
cytokine-expressing tumors. Populations are presented as the percentage of to
periments, plotted as mean ± SEM from individual tumors (n = 6).
See also Figure S3.
Cancontribute to T cell interactions in tumors and when present
near the margin are capable of competing for T cell occupancy.
Rare Tumor CD103+ DC2s Are Required for Efficient
Adoptive T Cell Therapy
We were surprised to find that the proportions of CD11b+ DC1
and CD103+ DC2 were nearly inverted in a spontaneously re-
gressing EG7 tumor model, hereto after referred to as EG7.2,
as compared with a fully aggressive and outgrowing line
EG7.1. While the aggressively growing tumors maintained the
relative proportions of DCs we observed in all other aggressive
tumors (Figure S6A), the spontaneously regressing model con-
tained unusually high numbers of the CD103+ DC2 (Figure S6B).
We also observed increased tumor growth in the Irf8 KO tumor
model, which lack CD103+ DC2, but not in the Irf4 conditional
KO model (Figures S6C and S6D). These together suggest that
DC2 tumoral abundance may play an important role in tumor
control; however, the differences in outgrowth may be caused
by many variances in these tumors beyond their populations of
myeloid cells and their ability to stimulate CTLs. To formally
test whether the CD103+ DC2s are necessary for efficient CTL-
mediated tumor regression, we turned to the outgrowing
EG7.1 tumor model and performed adoptive T cell therapy of
activated tumor specific T cells (Helmich and Dutton, 2001).
We performed these experiments in zDC-DTR mice, which
permitted us to specifically ablate CD103+ DC2 in the tumor (Fig-
ure 3D). In order to isolate the effect of the CD103+ DC2 to the
site of the tumor and eliminate any effect of LN priming, we
designed the experiment to include two strategies: (1) use of
activated OT-I CD8+ CTL blasts, which do not require priming
in the LN and typically do not traffic there and (2) treatment of
animals with the SIP1R antagonist FTY-720, which prevents LN
exit of rare transferred CTL T cells that traffic to the LN. The effect
of FTY-720 alone had minimal effects on transferred CTLs to
mediate tumor regression (Figure S6E). However, we found
that ablation of CD103+ DC2s in the context of FTY-720 had a
significant effect on the ability of CTLs to mediated efficient
tumor regression, massively slowing T-cell-mediation tumor
regression (Figure 8A).
Signatures of Intratumoral CD103+ DC2 Abundance
Predict Outcome across Human Cancer
To determine whether a critical role for CD103+ DC2 abundance
translated to human tumors, we took advantage of TCGA data
(Weinstein et al., 2013; Hoadley et al., 2014) that quantifies rela-
tive gene expression from numerous human cancer types with
matched outcome data. We used our RNAseq data to select
for high level transcripts that characterized CD103+ DC2 and
also selected a subset of genes that characterized TAM1/
TAM2/CD11b+DC1 cells but were deficient in CD103+ DC2.
We identified human homologs of those mouse genes and
assayed expression of these genes in TCGA data from all cancer
types to assess prognostic associations. In a proportional haz-
ards survival analysis, adjusting the model for cancer type as a6C MHCII+, CD24+) between ectopic B16-F10, B16-GMCSF, and B16-FLT3L
tal MHCII+ cells for each tumor. Data are pooled from three independent ex-
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Figure 5. Unique Antigen Processing and Presentation Capabilities of CD103+ DC2
(A) Heat map of log2-transformed expression from RNAseq across populations for selected genes involved in cross-presenting, cytokine and chemokine pro-
duction, and costimulation. The color scale is defined as green = bottom 20th percentile and red = top 80th percentile, with 20th to 80th percentile graduated and
centered at yellow (50th percentile). Data are from biological triplicates of sorted cells.
(B) Cytometry of surface protein levels of ligands for T-cell-regulatory molecules (colored) as compared with respective isotypes (gray).
(C) Cytometry of MCHI and MHCII (colored) expression compared with respective isotype (shaded).
(legend continued on next page)
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Figure 6. CD103+ DCs Are Superior T Cell
Stimulators for Naive and Activated CD8+
T cells
(A) Flow cytometry of early activation markers
Nur77GFP and CD69 (12 hr) on naive or previously
activated OT-I CD8+ T cells cultured on sorted
APC populations directly from tumors.
(B) Representative cytometry of naive OT-I CD8+
T cell proliferation, measured by dye dilution of
eFluor670 plotted against Nur77GFP (as measure
of TCR triggering), at 72 hr following coculture with
tumor APC populations. The total cell yield counts
are listed above the graphs.
(C) Histogram overlay of naive T cell proliferation
between tumor APCs.
(D) Representative cytometry of T cell proliferation,
measured by dye dilution of eFluor670 plotted
against Nur77GFP at 72 hr for previously activated
OT-I CD8+ T cell blasts cultured on tumor APC
populations. Total cell yield counts are listed
above the graphs.
(E) Histogram overlay of previously activated OT-I
CD8+ T cell proliferation across tumor APCs.
(F) Representative cytometry of T cell proliferation,
measured by dye dilution of eFluor670, at 72 hr for
naive OT-II CD4+ T cells cultured on tumor APC
populations. Representative flow plots are from
two independent experiments.
(G) Histogram overlay of naive OT-II CD4+ T cell
proliferation across tumor APCs.
All data are from the ectopic B78chOVA
tumor model: T cells + BMDC (shaded gray),
T cells + BMDC + SL8 (unshaded gray), T cells +
tumor APCs (respective colored histograms).
These are plated at 20,000 T cells: 4,000
APC. Representative flow plots are from four in-
dependent experiments, unless noted. See also
Figure S5.
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CD103+ DCs Drive T-Cell-Mediated Tumor Rejectioncovariate, we observed that the individual genes from these pop-
ulations had only modest prognostic benefits (expressed as haz-
ard ratio [HR]). In order to represent the relative proportion of the
two cell types, we defined a ratio of the CD103+ and CD103
gene expression data and used this as a continuous variable
within the Cox analysis. High expression of this ratio was signif-
icantly associated with increased overall survival (Benjamini-
Hochberg [BH] p = 0.00019) (Figure 8B).
This analysis shows that the cell type we identified, when
ratioed with its functional opposite, generates a very strong(D) Cytometry of ex vivo dextran uptake across populations. The gray shows no d
shows dextran uptake at 37C, displayed in triplicate. Delta geometric mean fluore
representative of two independent experiments (n = 6).
(E) Cytometry analysis of relative pH of endocytic compartments across populat
mCherry-pHlourin. Representative histograms show florescence of pHluorin in m
histograms are respective populations from a non-pHluorin expressing control tum
mCherry fluorescence. Data are presented as mean ratio ± SEM, pooled from th
(F) Intracellular cytokine stain of IL-12 in populations. The percentage of IL-12+ ce
experiments (n = 3) and plotted as mean ± SEM. Statistical significance is indica
(G) Il12b and Il10 transcript levels, measured by qPCR. Data are presented as me
(N.D., not detected).
All data are from the ectopic B78chOVA tumor model. See also Figure S4.
Canprognostic value for outcome across human cancers.
Comparing this ‘‘signature’’ with other previously described ‘‘im-
mune scores’’ shows that the ratio of CD103+/CD103 genes
provides the strongest proimmune survival signal compared
with other current analyses of TCGA data, including those based
on total T cell abundance (Palmer et al., 2006) and that made by
bulk ratio of CD8 T cells to macrophages (CD8/CD68; DeNardo
et al., 2011) (Figure 8C). Our score also compares favorably,
though opposite in prognosis, for those immune scores associ-
ated with poor outcome. It is also notable that CSF1 expressionextran. The light histogram shows dextran binding at 4C, and dark histogram
scence intensity (gMFI) for each population is plotted asmean ± SEM. Data are
ions. B78 tumor cells were transfected with the ratiometric pH construct, N1-
Cherry+ cells, where less pH-GFP represents a more acidic environment. Gray
or (B78 parental). Data are summarized as the ratio of gMFI between GFP and
ree independent experiments.
lls is quantified across each population. Data are pooled from two independent
ted by *p < 0.05.
an D Ct ± SEM calculated from biological triplicates (n = 3) of individual tumors
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Figure 7. Intravital and Slice Imaging Re-
veals that CD11b+ DC1 and CD103+ DC2
Are Sparse Near Tumor Margins yet Can
Interact with T Cells When Present There
(A) Representative cytometry of tumor APCs in
PyMTchOVA x Cx3cr1-eGFP 3 Cd11c-mCherry.
Populations as previously defined are plotted as
mCherry versus GFP. Green, yellow, and red cir-
cles indicate the fluorescent profile that each
population displays in this model. Red (mCherry
only cells), yellow (mCherry and GFP double-
positive cells), and green (GFP only cells) are
shown. By flow cytometry, DC1/DC2 populations
fall in the Cherry-only population, while TAM1 and
TAM2 comprise the yellow and green populations,
respectively.
(B) Intravital 2-photon representative still image of
an early carcinoma lesion from a PyMTchOVA 3
Cx3cr1-eGFP 3 Cd11c-mCherry reporter. Re-
gions indicated with a dashed line, marked either
distal or marginating to lesions, were determined
with a combination of mCherry fluorescence and
collagen structure. Collagen fibers are marked
(white) by second harmonic generation. The scale
bar represents 50 mm. (Inset) Quantification of the
proximal/distal location of the APCs within the tu-
mor. Data pooled from four independent imaging
runs, presented as mean ± SEM.
(C) Representative confocal still image from live
tumor slices in PyMTchOVA 3 Cx3cr1-eGFP 3
Cd11c-mCherry tumors, stained with CD11b-
A647 antibody. mCherry only cell (arrowhead DC2,
red) and mCherry+ CD11b+ cell (arrow DC1,
purple) in the tumor. Scale bar 15 mm.
(D) Representative image sequence of CFP ex-
pressing OT-1 CD8+ T cells (blue) dynamically in-
teracting with APC cells in the PyMTchOVA 3
Cx3cr1-eGFP3Cd11c-mCherrymodel by live slice
confocal imaging 4 days after T cell transfer at 0, 30,
and 60 min. The arrows indicate T cell interactions
with red (DC1/DC2), green (TAM1), or yellow (TAM2)
cells. The scalebar represents30mm.The last panel
displays time projection of CFP expressing T cells
through 60 min imaging timeframe, with outline
color dictated by APC of contact.
(E) APC-T cell contacts in vivo as a percentage of the total T cell couples observed. Accumulated data are shown of four different positions imaged for 30 min in
two independent intravital 2 photon imaging runs. Contacts were scored manually by counting physical contact made between T cells and red, yellow, and green
APCs. The color of bar represents the APC of contact (red: CD103+, CD11b+ DC1; green: TAM1; yellow: TAM2).
(F) Ex vivo T-cell-coupling assay with digested tumor positively selected for CD45+ cells with previously activated OT-I CD8+ T cell. Data are calculated as
percentage of T cells couples within each of the populations (left) and as a total percentage of T cell couples (right). Data are pooled from two independent
experiments, plotted as mean ± SEM.
See also Movies S1 and S2.
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BDCA3 gene ratio measure, although it likewise anticorrelates
with total tumor FLT3L levels (Figures S6F and S6G).
Finally, we sought to analyze the TCGA data within individual
cancer types. Adjusting for cancer type, a Kaplan-Meier (K-M)
plot for all 12 cancers in this data set shows the overall benefit
in tumors with a high CD103+/CD103 gene-expression profile
(Figure 8D; unadjusted plot in Figure S6H). The extent of this as-
sociation is particularly profound in breast cancer, head-neck
squamous cell carcinoma, and lung adenocarcinoma (Figures
8E–8G). Overall, this represents an unexpectedly strong immune
signature, the more so as it was derived entirely from empirical
immunoprofiling in mouse tumor models.648 Cancer Cell 26, 638–652, November 10, 2014 ª2014 Elsevier IncDISCUSSION
A critically important feature of this work is that within the diverse
array of myeloid cells at the tumor, a rare population of proim-
mune DCs exists even in immunoevasive tumors. This contrasts
with previous characterizations of the myeloid lineage in tumors
that have highlighted their immunosuppressive functions. This
study puts a face and a name on a specific subset of intratumoral
DCs whose functions one would wish to enhance as part of
immunotherapy and serves to begin to demystify the complexity
of this critical compartment.
This work provides an understanding of the tumoral myeloid
environment as having lineage parallels to other nontransformed.
Tu
m
or
 A
re
a 
m
m
2
0
50
100
150
0 2 4 6 8 10 12 14day
A
+/
- D
T
+ 
O
T-
1 
T 
ce
lls
 
 
+/
-F
TY
+DT + FTY 
No T cells
+PBS + FTY
B
Gene/Signat. Type HR [95% CI] p value BH p val 
CD103+/- RATIO RATIO 0.792 [0.719-0.872] 2.23E-06 6.47E-05 
KIT 0.896 [0.826-0.972] 0.00841 0.0264 
CCR7 0.905 [0.84-0.976] 0.00912 0.0264 
CD103+ Genes 0.907 [0.838-0.981] 0.0152 0.0399
BATF3 1.1 [1.02-1.2] 0.0165 0.0399
FLT3 0.862 [0.745-0.997] 0.0458 0.0781
ZBTB46 1.07 [0.985-1.16] 0.11 0.168 
IRF8 0.952 [0.886-1.02] 0.182 0.254 
BTLA 0.957 [0.879-1.04] 0.306 0.403 
MYCL1 
CLEC9A CD103+  0.976 [0.895-1.06] 0.583 0.604 
C5AR1 1.12 [1.06-1.19] 0.00014 0.00203 
LYVE1 1.15 [1.06-1.24] 0.00062 0.00502 
ABCC3 1.17 [1.07-1.29] 0.000693 0.00502 
MRC1 1.14 [1.05-1.23] 0.00162 0.0094 
SIGLEC1 1.11 [1.04-1.19] 0.00202 0.00976 
CD103- Genes 1.12 [1.03-1.21] 0.00541 0.02 
STAB1 1.09 [1.03-1.16] 0.00551 0.02 
C1QB 1.1 [1.01-1.19] 0.0218 0.052 
C1QA 1.1 [1.01-1.19] 0.0233 0.052 
TMEM37 0.889 [0.801-0.987] 0.0278 0.0576 
MERTK 0.93 [0.869-0.996] 0.0392 0.0758 
C1QC 1.07 [0.986-1.16] 0.106 0.168 
TMEM119 1.05 [0.976-1.13] 0.184 0.254 
MS4A7 1.04 [0.961-1.13] 0.322 0.406 
APOE CD103- 1.04 [0.943-1.14] 0.438 0.529 
CYP4F18 CD103-  1.03 [0.951-1.11] 0.477 0.532 
TREM2 CD103-  1.02 [0.943-1.11] 0.583 0.604 
TLR7 CD103-  1.01 [0.937-1.08] 0.868 0.868 
CD103- 
CD103-  
CD103-  
CD103-  
CD103- 
CD103-  
CD103-  
CD103-  
CD103- 
CD103-  
CD103-  
CD103-  
CD103-  
CD103-  
CD103+  
CD103+  
CD103+  
CD103+  
CD103+  
CD103+  
CD103+  
CD103+  
CD103+  
0.969 [0.892-1.05] 0.459 0.532 
D
CD103pos/neg=LOW
CD103pos/neg=HIGH
n=1801
n=1801
p value = 2.31e-06
O
ve
ra
ll 
S
ur
vi
va
l
Time in years
0 2 4 6 8 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
*
Signature OS Assoc. HR [95% CI] p value BH p val
CD103+/- Ratio Increased 0.79 [0.719-0.87] 2.23E-06 1.34E-05 
T Cell Increased  0.848 [0.76-0.93] 0.00096 0.00144 
CD8/CD68 Ratio Increased  0.908 [0.85-0.96] 0.00315 0.00378 
Proliferation Decreased 1.19 [1.08-1.31] 0.00047 0.00142 
CSR/Wound Decreased  1.18 [1.07-1.3] 0.00092 0.00144 
IFNG Decreased  1.12 [1.03-1.21] 0.00479 0.00479 
Time in years
p value = 0.00373
0 2 4 6 8 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
n=422
n=423
E
O
ve
ra
ll 
S
ur
vi
va
l
LOW ratio
HIGH ratio
0 2 4 6 8 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
n=151
n=152
F
O
ve
ra
ll 
S
ur
vi
va
l
Time in years
p value = 0.06.92E-05
LOW ratio
HIGH ratio
0 2 4 6 8 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
n=177
n=178
G
O
ve
ra
ll 
S
ur
vi
va
l
p value = 0.034
Time in years
LOW ratio
HIGH ratio
C
Figure 8. Rare CD103+ DC2 Population at the Tumor Is Required for Efficient Adoptive CTL Therapy
(A) Tumor growth curve plotted as tumor area (mm2) over time for EG7.1 in zDC-DTR hosts. The arrows indicate time of intraperitoneal DT/PBS administration,
and intravenous transfer of 5 3 106 previously activated OT-I CD8+ T cells. DT/PBS was subsequently administered every third day, and FTY-720/saline was
subsequently administered every other day throughout time course. Representative data are presented as mean tumor area ± SEM (n = 4) from two independent
experiments. Statistical significance is indicated by *p < 0.05.
(B) Comparison of prognostic value of CD103+/CD103 ratio gene signal as compared with the individual genes (either CD103+ specific, green, or TAM1/TAM2/
CD11b DC1 specific genes, red) using TCGA data sets in a multivariate COX proportional hazards survival analysis adjusting for cancer type as a covariate. Data
are expressed as HR with 95% confidence intervals, where a value <1 means increased overall survival (OS); >1 means decreased OS for genes with BH
p values < 0.05 (bolded values).
(C) Comparison of the prognostic value of the CD103+/CD1033 ratio gene signal with several published prognostic gene signatures using TCGA data sets in a
multivariate COX proportional hazards survival analysis adjusting for cancer type as a covariate. Data are expressed as HR with 95% confidence intervals, where
a value <1 means increased overall survival (OS); >1 means decreased OS for genes with BH p values < 0.05.
(D) K-M plot across all 12 cancer types in human TCGA data sets, adjusting for cancer type based on high CD103+/CD1033 gene ratio and low CD103+/
CD1033 ratio expressers (median split/cancer).
(E) K-M plot for overall survival of breast cancer patients in TCGA data set. Data are parsed on high CD103+/CD1033 gene ratio and low CD103+/CD1033 ratio
expressers.
(F) K-M plot for overall survival of head and neck squamous cell carcinoma patients in TCGA data set. Data are parsed on high CD103+/CD1033 gene ratio and
low CD103+/CD1033 ratio expressers.
(G) K-M plot for overall survival of lung adenocarcinoma patients in TCGA data set. Data are parsed on high CD103+/CD1033 gene ratio and low CD103+/
CD1033 ratio expressers.
See also Figure S6.
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Cancer Cell
CD103+ DCs Drive T-Cell-Mediated Tumor Rejectiontissues. Significant confusion in the current literature of myeloid
subpopulations results from inappropriate grouping of cells
(e.g., CD11b+) or from lack of a common method for distin-
guishing the various subpopulations (e.g., CD11c expression).
Recent additions to the repertoire of antibody markers and total
expression-array analyses of DCs versus macrophages versus
monocytes provided significant clarity to this situation (Gautier
et al., 2012; Miller et al., 2012). In particular, while conventional
DCs are seen to express one or more of markers such as CD24,
TAMs are better described through surface expression of F4/
80, CD64, and MerTK. To that end, CD11b+ DC1s in tumors
appear, by RNA expression and surface expression, to be
more closely allied to macrophages. This proximity of these
cells has been observed in other peripheral sites (Gautier
et al., 2012). In general, a remarkable similarity in IRF4-,
IRF8-, and Batf3-dependent origins and surface phenotypes
suggests that the overall origins and distinctions of tumor-infil-
trating myeloid cells is quite similar to counterparts in normal
tissues.
Our studies confirm earlier work showing that mice deficient
of Batf3 failed to spontaneously clear highly immunogenic tu-
mors (Hildner et al., 2008). However, our studies provide the
additional insight that the key populations defined by Batf3
and IRF8, but not IRF4 expression, are not only present and
functional within tumors but in fact are required for productive
responses to adoptively transferred CTLs generated in vitro, af-
ter T cells are already primed and in the absence of profound LN
involvement. This places at least some of the key Batf3- and
now IRF8-dependent cells as playing key roles in repriming
within the tumor. Thus, our understanding shifts emphasis
from the LN to the tumor for T cell control. Our work also puts
these cells in context in the tumor and shows that, while they
may be sporadically present on the tumor margins where
T cells will encounter their APCs, they are very sparse there.
Clinically, this suggests that enhancement of the intratumoral
load of these cells will be an important cofactor defining the suc-
cess of adoptive T cell therapies and broadly that providing re-
stimulation within the tumor represents an important require-
ment for T cell function at that site. That the requirement for
CD103 cells is intratumoral is further supported by our TCGA
analysis in which gene-expression data used to assess prog-
nostic value derive exclusively from mRNA taken from the tumor
but not the LN.
While our data did not show an absolute dependence on
CD103+ DC2 to facilitate adoptive CTL control of tumor
outgrowth, the effect was profound. It is not clear whether resid-
ual T-cell-dependent control in the DT-treated cohort might
represent myeloid-independent activity of these cells, a
compensatory role by other myeloid cells (e.g., CD11b+ DC1,
which stimulate CTL extremely weakly in vitro) or merely our
inability to fully eliminate the CD103+ DC2 population. To that
last possibility, it will be increasingly important to more effec-
tively manipulate the relative population densities of myeloid
cells, sparing the CD103+ DC2 or even providing means to
enhance them. Our demonstration of enhanced CD103+ DC2
generation in FLT3L expressing tumors provides a compelling
rationale as to why such therapy may work and indeed may be
synergistic with T cell therapies such as anti-CTLA4 (Curran
and Allison, 2009). Conversely, the efficacy of a-CSF1 therapies650 Cancer Cell 26, 638–652, November 10, 2014 ª2014 Elsevier Inc(Ries et al., 2014; Strachan et al., 2013) may be in part due to the
sparing of CD103+ DC2 under such blockade, as demonstrated
in our work.
Despite significantly increased clarity of the identities of intra-
tumoral myeloid populations and their similarities to those in
normal tissues, much remains to be elucidated concerning the
additional functional diversity of the intratumoral APCs. In partic-
ular, the role of CD11b+ DC1 in the tumor remains obscure. Their
transcriptional profiling and surface markers may place them
closer in identity to TAMs as compared with CD103+ DC2, which
is found in other macrophage populations from healthy periph-
eral sites (Gautier et al., 2012). We also note that these highly
resemble recently described ‘‘DC-Th2,’’ defined by their reliance
on the transcription factor IRF4, expression of CD301b and
PDL2, and ability to effectively prime Th2 responses (Gao
et al., 2013; Kumamoto et al., 2013; Williams et al., 2013). At
present, we failed to find a DC population that could robustly
stimulate CD4 T cells when taken directly from the tumor; how-
ever, DC1 and DC2 could be rescued upon add back of peptide,
suggesting either that the MHCII processing pathway is not
highly active in these cells or that our digest conditions affect
MHCII antigen loading. Regardless, this may reinforce the hy-
pothesis that the absence of effective T cell help and its atten-
dant gc cytokine production are critical missing links in the tumor
microenvironment.
Our study of these cell types now brings to the forefront many
spatiotemporal issues about how the various myeloid popula-
tions interface with tumors, with one another, and with T cells.
While it is clear from our imaging that the marginating cells are
dominated by TAM1 and TAM2, the nature of ‘‘APC selection’’
by T cells is not fully resolved. Do CTLs with particular activation
choose particular subsets of myeloid cells, and conversely, does
the in situ interaction of T cells with CD103+ DC2 give them abil-
ities to kill so long as they do not encounter a TAM in the interim?
Many of these types of questions will require elaboration of spec-
tral labeling methods. In addition, these types of approaches will
require significant adoption and/or development of biosensor-
like reporters to determine where and when complete TCR
signaling is taking place.
Finally, a very important finding of this study relates to the
applicability of the myeloid delineation to multiple human tu-
mors. Using bioinformatics based on these populations, we
observed that CD103+ DC2-enriched transcripts, taken from
mouse models and expressed as a ratio with an equivalent
selection from the TAM/DC1 populations, provides a strong
prognostic signal in TCGA data, across multiple tumor types.
The fact that this ‘‘signature’’ correlates with patient survival
better than other published signatures provides an additional
and compelling reason to suggest that this population is critical
for robust tumor control in mice and humans. Clearly, additional
profiling of these populations in context of immunotherapies will
be required to test this further and should be undertaken along-
side all further immunotherapy trials. It will be particularly inter-
esting to determine whether patients having CD103/BDCA3
‘‘high’’ tumors will represent better responders to checkpoint
blockade. In sum, it is clear that these rare cells should now be
a target to augment their numbers as well as a biomarker that
may define those whose immune response is well positioned
to eliminate cancers..
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Mouse Tumors
PyMT-ChOVA transgenic C57BL/6 founder mice were as described (Engel-
hardt et al., 2012), and offspring were screened for the PyMT-ChOVA
transgene by PCR and monitored for tumors and used at 20 to 30 weeks of
age. B78ChOVA is a variant of B78 (Graf et al., 1984) and is generated and
used as described in Supplemental Experimental Procedures. All additional
strain information can be found in supplemental methods. All mice were main-
tained under specific pathogen free (SPF) conditions and treated in accor-
dance with the regulatory standards of the NIH and American Association of
Laboratory Animal Care standards and are consistent with the UCSF Institu-
tion of Animal Care and Use Committee (IACUC approval: AN106779-01A).
Flow Cytometry
All antibodies were purchased from BD Pharmingen, eBioscience, Invitrogen,
Biolegend, and the UCSF hybridoma core or were produced in the Krummel
Lab. For surface staining, cells were incubated with anti-Fc receptor antibody
(clone 2.4G2) and stained with antibodies in PBS + 2% fetal calf serum for
30 min on ice. Viability was assessed by staining with fixable Live/Dead Zombie
(Biolegend) or 40,6-diamidino-2-phenylindole. For intracellular staining, mice
were injected with 10 mg/g of body weight with Brefeldin A (Cayman) 6 hr prior
to harvest. Cells were stained with antibodies against surface markers and
then fixed with 2% paraformaldehyde for 10 min at 25C and permeabilized
with 0.2%saponin then stainedwith target antibody. All flow cytometry was per-
formed on a BD Fortessa flow cytometer. Analysis of flow cytometry data was
done using Flowjo (Treestar). Cell sortingwasperformedusing aBDFACSAria II.
Human Samples
Tissue was vigorously minced with surgical scissors and transferred to a 25 ml
Erlenmeyer with magnetic stir bar with 3 mg/ml collagenase A (Roche) and
50 U/ml DNase I (Roche) per 0.3 g of tissue for 1 hr at 37C and 5% CO2
with constant agitation. Samples are then filtered through a 70 mm filter,
spun down, and resuspended for staining. For all human samples, informed
consent was obtained from all subjects, and work was performed in accor-
dance with institutional review board (IRB) approval (IRB number 13-12246,
12/06/2013-12/05/2014).
TCGA Bioinformatics Analysis
Clinical expression analysis uses genome-wide mRNA levels (Illumina mRNA-
seq) from 3,602 patient tumor samples representing 12 cancer types (845
breast, 265 ovarian, 303 head and neck squamous, 122 bladder, 168 glioblas-
toma, 190 colon, 173 acute myeloid leukemia, 72 rectal, 355 lung adenocarci-
noma, 259 lung squamous, 480 kidney, and 370 uterine cancers), normalized,
and combined into a single data set by the TCGA PanCancer working group as
published (Weinstein et al., 2013; Hoadley et al., 2014) (data are in the
TCGA Data Portal [https://tcga-data.nci.nih.gov/tcga/] and available as
syn1715755 at https://www.synapse.org/). The CD103+/CD103 ratio signa-
ture is calculated as the log of the mean expression of CD103+ DC genes
divided by the mean expression of the CD103 DC genes, followed by Z score
standardization (mean = 0, SD = 1; gene list in Figure 8C). We also evaluate
published T cell (Palmer et al., 2006), proliferation (Wolf et al., 2014), CSR/
wound (Chang et al., 2005), and gamma interferon (Viigimaa et al., 2010) sig-
natures as published, along with a CD8/CD68 expression ratio (DeNardo
et al., 2011). Overall survival data were obtained from the TCGA portal (down-
loaded 6/2013) (Weinstein et al., 2013) and survival analysis performed using
Cox proportional hazards modeling in a multivariate model adjusting for can-
cer type. Log-rank p values are used to assess significance after adjusting
for multiple comparisons using the BH method (Bejamini and Hochberg,
1995). K-M survival plots are generated using the Survival package in R. In
the all-data KM plot (Figure 8E), we adjusted for cancer type by classifying
each sample as ‘‘high’’ or ‘‘low’’ using that cancer types’ median value of
the CD103+/CD103 ratio signature.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software. Unless
specifically noted, all data are representative of more than three separate ex-
periments. Error bars represent SEM calculated using Prism and are derivedCanfrom triplicate experimental conditions. Specific statistical tests used were
paired and unpaired t tests, and all p values less than 0.05 were considered
statistically significant.
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